Open Label, Phase II Study of TGR-1202 in Patients With Relapsed or Refractory (R/R) Grade 1, 2, or 3A Follicular Lymphoma (FL) - Stand Up To Cancer

Blog

Posted October 11, 2019

Open Label, Phase II Study of TGR-1202 in Patients With Relapsed or Refractory (R/R) Grade 1, 2, or 3A Follicular Lymphoma (FL)

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.